Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Vs. Novo Nordisk, Eli LillyInvestors Business Daily • 06/26/23
Pfizer to advance oral candidate danuglipron as treatment for obesity and diabetes toward late-stage trial and discontinue lotiglipronMarket Watch • 06/26/23
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes MellitusBusiness Wire • 06/26/23
FDA Approves Pfizer's LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia AreataBusiness Wire • 06/23/23
Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis saysCNBC • 06/22/23